CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-10-06 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −70,000 | 116,848 | ||
| 2010-10-05 | Almon Einat Brill VP, Product Development | Sale | −20,000 | $9.08 | $182K | 0 |
| 2010-10-04 | Almon Einat Brill VP, Product Development | Sale | −35,000 | $9.02 | $316K | 0 |
| 2010-09-07 | Maimon Yossi VP, Chief Financial Officer | Sale | −31,500 | $8.16 | $257K | 0 |
| 2010-09-07 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +70,000 | $0.97 | $68K | 0 |
| 2010-09-07 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −70,000 | 153,733 | ||
| 2010-09-07 | Almon Einat Brill VP, Product Development | Sale | −22,500 | $8.16 | $184K | 0 |
| 2010-09-07 | Almon Einat Brill VP, Product Development | Option exercise | +4,740 | $0.40 | $2K | 0 |
| 2010-09-07 | Almon Einat Brill VP, Product Development | Option exercise | +45,260 | $0.97 | $44K | 0 |
| 2010-09-07 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −4,740 | 0 | ||
| 2010-09-07 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −45,260 | 186,848 | ||
| 2010-09-03 | Maimon Yossi VP, Chief Financial Officer | Sale | −38,500 | $8.00 | $308K | 0 |
| 2010-09-03 | Almon Einat Brill VP, Product Development | Sale | −27,500 | $8.00 | $220K | 0 |
| 2010-08-29 | Palash Tzvi Chief Operating Officer | Grant or award · Stock Options (Right to Buy) | +160,000 | 160,000 | ||
| 2010-08-06 | Shaaltiel Yoseph Executive VP, R&D | Sale | −4,619 | $7.00 | $32K | 763,754 |
| 2010-08-05 | Shaaltiel Yoseph Executive VP, R&D | Sale | −48,408 | $7.00 | $339K | 768,373 |
| 2010-06-21 | Shaaltiel Yoseph Executive VP, R&D | Sale | −52,973 | $7.00 | $371K | 816,781 |
| 2010-04-29 | Shaaltiel Yoseph Executive VP, R&D | Sale | −12,691 | $7.00 | $89K | 869,754 |
| 2010-04-14 | Shaaltiel Yoseph Executive VP, R&D | Sale | −1,309 | $7.00 | $9K | 882,445 |
| 2010-03-25 | Shaaltiel Yoseph Executive VP, R&D | Sale | −50,000 | $7.00 | $350K | 883,754 |
Page 9 of 33 · 654 trades